NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Maraia Tanner is the CEO of Star Harbor based in Lone Tree, Colorado. She shares insights into the mission of the organization and how...
In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he...
TMI is developing the POINT-GUARD, the first and only cerebral embolic protection device with dynamic Double-Edge Sealing. The seal adapts and conforms to complex...
